Inozyme Pharma (INZY) News Today → He Is Giving Away Bitcoin (From Crypto Swap Profits) (Ad) Free INZY Stock Alerts $4.64 +0.04 (+0.87%) (As of 05/8/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineInozyme Pharma Inc.: Inozyme Pharma Reports First Quarter 2024 Financial Results and Provides Business Highlightsfinanznachrichten.de - May 8 at 6:10 PMInozyme Pharma GAAP EPS of -$0.38 beats by $0.02msn.com - May 8 at 6:10 PMInozyme Pharma Buy Rating Affirmed on Strong Trial Results and Robust Pipeline Prospectsmarkets.businessinsider.com - May 8 at 6:10 PMAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Inozyme Pharma (INZY), Esperion (ESPR) and Madrigal Pharmaceuticals (MDGL)markets.businessinsider.com - May 8 at 6:10 PMAnalysts Offer Insights on Healthcare Companies: Cogent Biosciences (COGT) and Inozyme Pharma (INZY)markets.businessinsider.com - May 8 at 8:58 AMInozyme Pharma (NASDAQ:INZY) Rating Reiterated by Needham & Company LLCmarketbeat.com - May 8 at 8:56 AMInozyme Pharma to Participate at the Bank of America Securities 2024 Health Care Conferenceglobenewswire.com - May 8 at 8:30 AMInozyme Pharma (NASDAQ:INZY) Receives "Outperform" Rating from Wedbushamericanbankingnews.com - May 8 at 6:06 AMInozyme Pharma's (INZY) Outperform Rating Reaffirmed at Wedbushmarketbeat.com - May 7 at 7:34 PMINZY Stock Earnings: Inozyme Pharma Misses EPS for Q1 2024investorplace.com - May 7 at 3:22 PMInozyme Pharma Reports First Quarter 2024 Financial Results and Provides Business Highlightsglobenewswire.com - May 7 at 8:30 AMInozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)globenewswire.com - May 3 at 8:30 AMAnalysts Are Bullish on These Healthcare Stocks: Inozyme Pharma (INZY), Moderna (MRNA)markets.businessinsider.com - April 9 at 1:51 PMBank of America Lowers Inozyme Pharma (NASDAQ:INZY) Price Target to $14.00marketbeat.com - April 9 at 1:31 PMNeedham & Company LLC Reaffirms "Buy" Rating for Inozyme Pharma (NASDAQ:INZY)marketbeat.com - April 9 at 8:24 AMInozyme Pharma's (INZY) "Outperform" Rating Reaffirmed at Wedbushmarketbeat.com - April 8 at 5:25 PMInozyme Reports Positive Topline Data From Phase 1/2 Study Of INZ-701; Stock Upmarkets.businessinsider.com - April 8 at 7:45 AMInozyme Pharma Announces Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency (PXE) and ENPP1 Deficiencyglobenewswire.com - April 8 at 6:30 AMInozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)globenewswire.com - April 5 at 6:00 PMInozyme Pharma, Inc. (NASDAQ:INZY) CEO Douglas A. Treco Sells 7,523 Sharesinsidertrades.com - April 4 at 6:52 AMInozyme Pharma to Participate at the 23rd Annual Needham Virtual Healthcare Conferenceglobenewswire.com - April 2 at 8:30 AMInozyme Pharma to Report Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency and ENPP1 Deficiency on April 8, 2024globenewswire.com - March 26 at 8:30 AMFY2024 EPS Estimates for Inozyme Pharma, Inc. Lowered by Analyst (NASDAQ:INZY)marketbeat.com - March 15 at 7:22 AMInozyme Pharma, Inc. (NASDAQ:INZY) to Post Q1 2024 Earnings of ($0.35) Per Share, HC Wainwright Forecastsmarketbeat.com - March 14 at 6:39 AMBuy Rating for Inozyme Pharma Backed by Promising Clinical Progress and Unique Market Positioning of INZ-701markets.businessinsider.com - March 13 at 2:02 PMInozyme Pharma: Q4 Earnings Insightsbenzinga.com - March 12 at 7:45 PMInozyme Pharma: Q4 Earnings Insightsbenzinga.com - March 12 at 7:45 PMBuy Rating Affirmed for Inozyme Pharma as Phase I/II Trial Updates and Strong Cash Position Bolster Confidencemarkets.businessinsider.com - March 12 at 7:45 PMBuy Rating Affirmed for Inozyme Pharma as Phase I/II Trial Updates and Strong Cash Position Bolster Confidencemarkets.businessinsider.com - March 12 at 7:45 PMInozyme Pharma: Strong Buy Rating Amidst Promising Trial Developments and Market Underappreciationmarkets.businessinsider.com - March 12 at 7:45 PMInozyme Pharma (NASDAQ:INZY) Stock Rating Reaffirmed by Wedbushmarketbeat.com - March 12 at 2:26 PMInozyme Pharma Inc.: Inozyme Pharma Reports Full Year 2023 Financial Results and Provides Business Highlightsfinanznachrichten.de - March 12 at 2:03 PMInozyme Pharma Reports Full Year 2023 Financial Results and Provides Business Highlightsglobenewswire.com - March 12 at 8:30 AMInozyme Pharma, Inc. (NASDAQ:INZY) Shares Purchased by Schonfeld Strategic Advisors LLCmarketbeat.com - March 10 at 5:38 AMFmr LLC Increases Stake in Inozyme Pharma, Inc. (NASDAQ:INZY)marketbeat.com - March 8 at 4:24 AMAdage Capital Partners GP L.L.C. Acquires 1,287,500 Shares of Inozyme Pharma, Inc. (NASDAQ:INZY)marketbeat.com - March 7 at 7:44 AMInozyme Pharma, Inc. (NASDAQ:INZY) Shares Purchased by Rock Springs Capital Management LPmarketbeat.com - March 5 at 7:37 PMEventide Asset Management LLC Makes New Investment in Inozyme Pharma, Inc. (NASDAQ:INZY)marketbeat.com - March 1 at 9:32 AMInozyme Pharma to Participate in the TD Cowen 44th Annual Health Care Conferenceglobenewswire.com - February 26 at 8:30 AMINZY May 2024 5.000 putfinance.yahoo.com - February 25 at 10:33 AMInozyme Pharma Stock (NASDAQ:INZY), Short Interest Reportbenzinga.com - February 24 at 5:50 PMBakker Juliet Tammenoms's Net Worthbenzinga.com - February 22 at 7:03 PMInozyme Pharma, Inc. (INZY)finance.yahoo.com - January 30 at 1:57 PMInozyme Pharma Inc Ordinary Shares INZYmorningstar.com - January 19 at 11:13 PMInstitutional investors own a significant stake of 45% in Inozyme Pharma, Inc. (NASDAQ:INZY)finance.yahoo.com - December 21 at 8:33 AMTD Cowen Reaffirms Their Buy Rating on Inozyme Pharma (INZY)markets.businessinsider.com - November 9 at 12:02 AMInozyme Pharma Reports Third Quarter 2023 Financial Results and Provides Business Highlightsfinance.yahoo.com - November 7 at 9:59 AMInozyme Pharma Announces Presentation at the American Society of Nephrology (ASN) Kidney Week 2023finance.yahoo.com - October 26 at 1:07 PMInozyme Pharma, Inc. (INZY) Moves to Buy: Rationale Behind the Upgrademsn.com - October 10 at 1:48 PMInozyme Pharma Highlights Inclusion of Generalized Arterial Calcification of Infancy (GACI) in Genomics England’s Generation Study of Rare Conditionsfinance.yahoo.com - October 10 at 8:47 AM Get Inozyme Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for INZY and its competitors with MarketBeat's FREE daily newsletter. Email Address 348 million Americans lives to END as we know it? (Ad)348 million American lives are about to change FOREVER.... Because thanks to one shocking A.I. development I'm revealing for the first time today... To see my free research, simply click here now. INZY Media Mentions By Week INZY Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. INZY News Sentiment▼-0.250.36▲Average Medical News Sentiment INZY News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. INZY Articles This Week▼151▲INZY Articles Average Week Get Inozyme Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for INZY and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: XOMA News Eliem Therapeutics News RAPT Therapeutics News XBiotech News Verastem News Xeris Biopharma News CytomX Therapeutics News Enanta Pharmaceuticals News Akebia Therapeutics News Nektar Therapeutics News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:INZY) was last updated on 5/9/2024 by MarketBeat.com Staff From Our PartnersTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsDems have chosen Biden replacement?Paradigm Press348 million Americans lives to END as we know it?The Oxford ClubThe A.I. story nobody is telling you (Read ASAP)TradeSmithGold Set to EXPLODE!Gold Safe ExchangeHow Biden has already won 2024Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inozyme Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
